Skip to main content

Table 5 WHO Classification: OS of patients with MDS or AML-MRF receiving AZA front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

WHO diagnosis

n

Median OS, mo

95 % CI, mo

p value

AML30-MRF

AML20–30-MRF

MDS-RAEB-II

MDS-RAEB-I

74

61

96

53

13.1

13.5

18.9

23.7

8.6–17.5

10.5–16.5

12.7–25.1

14.4–33.0

0.001a

AML30-MRF

AML20–30-MRF

74

61

13.1

13.5

8.6–17.5

10.5–16.5

0.474

AML20–30-MRF

MDS-RAEB-II

61

96

13.5

18.9

10.5–16.5

12.7–25.1

0.033b

MDS-RAEB-II

MDS-RAEB-I

96

53

18.9

23.7

12.7–25.1

14.4–33.0

0.302

  1. aHR = 1.247; 95 % CI 1.118–1.392
  2. bHR = 1.551; 95 % CI 1.032–2.331
  3. WHO World Health Organization, OS overall survival, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, MRF MDS-related features, AZA azacitidine, CI confidence interval, RAEB refractory anaemia with excess blasts, HR hazard ratio